title: IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
authors.forename: L
authors.initials: L
authors.lastname: Naumann
authors.forename: E
authors.initials: E
authors.lastname: Feist
authors.forename: A
authors.initials: A
authors.lastname: Natusch
authors.forename: S
authors.initials: S
authors.lastname: Langen
authors.forename: A
authors.initials: A
authors.lastname: Krause
authors.forename: F
authors.initials: F
authors.lastname: Buttgereit
authors.forename: G-R
authors.initials: GR
authors.lastname: Burmester
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1